Elbert D. Glover
Professor Emeritus, Behavioral and Community Health
eglover1@umd.edu (301) 405-2029Dr. Glover is an Emeritus Professor in the Department of Behavioral and Community Health and Founding Director of the Center for Health Behavior Research at the Maryland School of Public Health, University of Maryland, College Park, MD. Dr. Glover has more than 200 publications and approximately $33 million dollars in grant funding to his credit.
He maintains a keen interest in the physician's role in smoking cessation & has delivered over 550 invited medical grand rounds/workshops on the subject to physicians throughout the world. Moreover, he has delivered over 335 national and international professional presentations to various medical & health professional organizations.
Department Information
- Department of Behavioral and Community Health
Distinguished Scholar for AAHE, 2003
Alliance Scholar for AAHPERD, selected by the University of Maryland as a “Rainmaker” which designates a Research Leader, 2005
American Academy of Health Behavior Research Laureate Medallion, 2008
HLTH688W Professional Writing
BA, Health Education, 1969
Texas Tech University, Lubbock, TX
MA, Health Education, 1972
Texas A & I University, Kingsville, TX
PhD, Health Education, 1977
Texas Woman’s University, Denton, TX
Hurt RD, Sachs DPL, Glover ED, Offord KP, Johnston JA, Dale LC, Khayrallah MA, Schroeder DR, Glover PN, Sullivan CR, Croghan IT, Sullivan PM. A comparison of sustained-release bupropion & placebo for smoking cessation. New England Journal of Medicine, 337:1195-1202.
Daughton D, Fortmann S, Glover ED, Hatsukami D, Heatley S, Lichtenstein E, Repsher L, MillatmalT, Killen J, Nowak R, Ullrich F, Rennard S. The smoking cessation efficacy of varying doses of nicotine patch delivery systems four years to five years post quit day. Preventive Medicine, 28:113-119.
Hayford KE, Patten CA, Rummans TA, Schroeder DR, Offord KP, Croghan IT, Glover ED, Sachs DPL, Hurt RD. Effectiveness of bupropion for smoking cessation in subjects with a history of major depression or alcoholism. British Journal of Psychiatry, 174:173-178.
Dale LC, Glover ED, Sachs DPL, Schroeder DR, Offord KP, Croghan IT, Hurt RD. Bupropion for smoking cessation—predictors of successful outcome. Chest, 119:1357-1364.
Johnston JA, Fiedler-Kelly J, Glover ED, Sachs DPL, Grasela T, DeVeaugh-Geiss J. Relationship between drug exposure and the efficacy and safety of bupropion sustained-release for smoking cessation. Nicotine & Tobacco Research, 3(2):131-140.